यूरोपीय संघ -
आइसलैंडी -
EMA (European Medicines Agency)
jemperli
glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.
यूरोपीय संघ -
आइसलैंडी -
EMA (European Medicines Agency)
xevudy
glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - Ónæmiskerfið sera og mótefni, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
lamictal tuggu-/dreifitafla 50 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 50 mg
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
lamictal tuggu-/dreifitafla 5 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 5 mg
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
lamictal tuggu-/dreifitafla 25 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 25 mg
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
lamictal tuggu-/dreifitafla 200 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 200 mg
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
lamictal tuggu-/dreifitafla 2 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 2 mg
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
lamictal tuggu-/dreifitafla 100 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 100 mg
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
serevent innúðalyf, dreifa 25 míkróg/skammt
glaxosmithkline pharma a/s - salmeterolum xínafóat - innúðalyf, dreifa - 25 míkróg/skammt
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
seretide innúðalyf, dreifa 25/250 míkróg/skammt
glaxosmithkline pharma a/s - salmeterolum xínafóat; fluticasonum própíónat - innúðalyf, dreifa - 25/250 míkróg/skammt